Cited In for PMID: 27067505

Year	Number of Results
2016	1
2017	1
2018	7
2019	2
2020	1
2021	3
2022	5
2023	3
2024	1

1

Targeted Radiolabeled Compounds in Glioma Therapy.

Cordier D, Krolicki L, Morgenstern A, Merlo A. Cordier D, et al. Semin Nucl Med. 2016 May;46(3):243-9. doi: 10.1053/j.semnuclmed.2016.01.009. Semin Nucl Med. 2016. PMID: 27067505 Review.

2

Targeted Glioma Therapy-Clinical Trials and Future Directions.

Shikalov A, Koman I, Kogan NM. Shikalov A, et al. Pharmaceutics. 2024 Jan 11;16(1):100. doi: 10.3390/pharmaceutics16010100. Pharmaceutics. 2024. PMID: 38258110 Free PMC article. Review.

3

Clinical Advances and Perspectives in Targeted Radionuclide Therapy.

Lepareur N, Ramée B, Mougin-Degraef M, Bourgeois M. Lepareur N, et al. Pharmaceutics. 2023 Jun 14;15(6):1733. doi: 10.3390/pharmaceutics15061733. Pharmaceutics. 2023. PMID: 37376181 Free PMC article. Review.

4

Peptides for trans-blood-brain barrier delivery.

Blades R, Ittner LM, Tietz O. Blades R, et al. J Labelled Comp Radiopharm. 2023 Jul;66(9):237-248. doi: 10.1002/jlcr.4023. Epub 2023 Apr 20. J Labelled Comp Radiopharm. 2023. PMID: 37002811 Free PMC article. Review.

5

CircNDC80 promotes glioblastoma multiforme tumorigenesis via the miR-139-5p/ECE1 pathway.

Wang Y, Wang B, Zhou F, Lv K, Xu X, Cao W. Wang Y, et al. J Transl Med. 2023 Jan 12;21(1):22. doi: 10.1186/s12967-022-03852-3. J Transl Med. 2023. PMID: 36635757 Free PMC article.

6

Identification of the miR-423-3p/VLDLR Regulatory Network for Glioma Using Transcriptome Analysis.

Song Y, Jiao H, Lin Q, Zhang X, Chen X, Wei Z, Yi L. Song Y, et al. Neurochem Res. 2022 Dec;47(12):3864-3901. doi: 10.1007/s11064-022-03774-y. Epub 2022 Nov 9. Neurochem Res. 2022. PMID: 36352275

7

Diffusing alpha-emitters radiation therapy in combination with temozolomide or bevacizumab in human glioblastoma multiforme xenografts.

Nishri Y, Vatarescu M, Luz I, Epstein L, Dumančić M, Del Mare S, Shai A, Schmidt M, Deutsch L, Den RB, Kelson I, Keisari Y, Arazi L, Cooks T, Domankevich V. Nishri Y, et al. Front Oncol. 2022 Sep 27;12:888100. doi: 10.3389/fonc.2022.888100. eCollection 2022. Front Oncol. 2022. PMID: 36237307 Free PMC article.

8

Transcriptome Analysis and Single-Cell Sequencing Analysis Constructed the Ubiquitination-Related Signature in Glioma and Identified USP4 as a Novel Biomarker.

Tang Q, Chen Z, Xie J, Mo C, Lu J, Zhang Q, Wang Z, Wu W, Wang H. Tang Q, et al. Front Immunol. 2022 Jun 14;13:915709. doi: 10.3389/fimmu.2022.915709. eCollection 2022. Front Immunol. 2022. PMID: 35774799 Free PMC article.

9

ANXA1: An Important Independent Prognostic Factor and Molecular Target in Glioma.

Zhang D, Wang W, Zhou H, Su L, Han X, Zhang X, Han W, Wang Y, Xue X. Zhang D, et al. Front Genet. 2022 May 31;13:851505. doi: 10.3389/fgene.2022.851505. eCollection 2022. Front Genet. 2022. PMID: 35711921 Free PMC article.

10

Overexpression of lncRNA IRAIN restrains the progression and Temozolomide resistance of glioma via repressing IGF-1R-PI3K-NF-κB signaling pathway.

Guo A, Fang G, Lin Z, Zheng S, Zhuang Z, Lin R, Lin Y. Guo A, et al. Histol Histopathol. 2022 Jun;37(6):543-554. doi: 10.14670/HH-18-425. Epub 2022 Feb 1. Histol Histopathol. 2022. PMID: 35102541

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

23 results

Results by year